Top 10 Scientists Behind The Development of Tirzepatide
The Architects of an Era: The Ten Scientists Who Engineered the Tirzepatide Revolution
For decades, the treatment of obesity and type 2 diabetes has been defined by compromise. Physicians managed blood sugar with insulin and metformin, patients struggled with weight through calorie restriction, and the concept of a single pharmacological agent that could achieve significant, sustained weight loss alongside superior glycemic control seemed like a distant dream. The discovery of leptin in the 1990s illuminated the molecular systems controlling food intake and energy homeostasis, yet despite enormous growth in scientific understanding, the only therapeutic approach offering weight loss of 20% or more remained bariatric surgery.
Then came GLP-1. The development of glucagon-like peptide-1 receptor agonists opened a new window of opportunity for reliable, significant medical weight loss at tolerable doses. But the pharmaceutical industry, ever in pursuit of the next breakthrough, faced a fundamental ceiling. How do you push efficacy beyond what single-receptor agonism can achieve without rendering the drug intolerable? The answer, as it turned out, lay not in replacing GLP-1, but in augmenting it—and in doing so, in fundamentally rethinking how peptide hormones could be engineered.
Enter tirzepatide. Marketed by Eli Lilly as Mounjaro for type 2 diabetes and Zepbound for obesity, this molecule is the first dual GIP and GLP-1 receptor agonist to reach the market. Its journey from a concept in peptide chemistry to a blockbuster therapy represents one of the most consequential drug development stories of the 21st century. The story of tirzepatide is not just one of a molecule, but of a constellation of scientific minds—peptide chemists, molecular biologists, pharmacologists, and clinical endocrinologists—who bridged the gap between complex peptide engineering and unprecedented clinical outcomes.
This is the definitive account of the ten scientists who built the foundation of the tirzepatide revolution.
1. Tamer Coskun: The Conceptual Revolution and the Birth of LY3298176
If there is a single figure most synonymous with the internal championing of tirzepatide at Eli Lilly, it is Dr. Tamer Coskun. As an MD and leading researcher at the company, Coskun served as the lead author of the foundational 2018 paper that introduced the scientific community to LY3298176—the internal code name for what would become tirzepatide.
Published in Molecular Metabolism, the paper, "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept," was the first comprehensive disclosure of the drug's preclinical and early clinical profile. It laid out the scientific rationale for why combining GIP and GLP-1 agonism into a single, once-weekly peptide could produce effects superior to existing GLP-1-based therapies.
Coskun's role extended far beyond authorship. He holds numerous patents for the drug's development and was a key architect of the strategy that ultimately brought it to market. His vision was grounded in a deep understanding of the incretin system—the metabolic axis that regulates postprandial metabolism through the two incretin peptides, GIP and GLP-1. While GLP-1 receptor agonism had already proven its clinical utility, Coskun and his team recognized that GIP, often dismissed as a "weak" contributor to insulin secretion in diabetics, might hold the key to unlocking a new level of efficacy when properly combined with GLP-1.
The 2018 paper demonstrated that the new molecule not only improved glycemic control but also induced weight loss in a dose-dependent manner. Coskun's leadership was instrumental in steering the compound through the treacherous waters of early development, where many promising molecules falter. In recent work, Coskun has continued to push the boundaries, investigating the combination of tirzepatide with novel agents like the selective amylin analog eloralintide to further enhance weight loss. His trajectory from the laboratory to the boardroom—where he now serves as Executive Director of Diabetes Research at Lilly—underscores the depth of his contribution.
2. Richard DiMarchi: The Foundation of Peptide Engineering
While Coskun led the charge at Lilly, the structural foundation for tirzepatide was laid years earlier by a pioneering peptide chemist operating at the intersection of academia and industry. Dr. Richard DiMarchi, currently at Indiana University, is a titan in the field of peptide engineering, with deep, historic ties to Eli Lilly.
DiMarchi’s groundbreaking work in peptide engineering has been instrumental in creating the structural backbone for many modern GLP-1 drugs. His group advanced the peptide clinical candidates and, critically, developed the unimolecular co-agonist concepts that directly led to the creation of tirzepatide. The core idea—that a single peptide could be engineered to potently activate two distinct receptors simultaneously—was a monumental leap from the traditional "one drug, one target" paradigm.
This challenge was not trivial. GLP-1 and GIP are sufficiently homologous to enable a single peptide sequence with high potency agonism at both receptors, but achieving the right "balance" of activity required painstaking rational design. DiMarchi's team employed combinatorial chemistry to create single molecules with multi-receptor potency comparable to the native incretins. The design strategy involved the interchange of specific GIP-derived amino acids, the addition of C-terminally extended residues from the reptilian GLP-1R agonist exendin-4, and the selection of non-canonical amino acids at key positions. The result was a peptide with subnanomolar, balanced activity at both incretin receptors and minimal activity at the glucagon receptor. The later addition of fatty acyl side-chains extended the duration of action by delaying renal clearance, enabling the once-weekly dosing that has made tirzepatide so commercially successful.
It is a testament to the relentless curiosity that defines the best scientific minds—never content to rest on past successes, always seeking the next evolution.
3. Brian Finan: The Biological Mechanist and the Physiology of Co‑Agonism
If Coskun and DiMarchi were the architects of the tirzepatide molecule, Dr. Brian Finan was the scientist who helped explain why it works. A leading metabolic scientist, Finan has worked extensively on the basic science of dual and triple incretin co-agonists.
Finan's research has been critical in explaining the complex biological mechanisms behind how GLP-1/GIP dual agonists function in the body. His work, often conducted in collaboration with other luminaries like Matthias Tschöp and Richard DiMarchi, explored the fundamental physiology of multi-receptor agonists. Early studies between 2006 and 2013 led to the creation of active GIPR/GLP-1R co-agonists, demonstrating that GIPR activation could bring valuable metabolic synergy in combination with GLP-1R agonism.
This was a controversial stance at the time. The mainstream view held that GIPR agonism added little to glycemic lowering in people with diabetes and could potentially be deleterious for weight gain. In fact, some experts advocated for GIPR antagonism as a therapeutic mechanism. Finan and his colleagues' work challenged this dogma. Their preclinical studies in obese mice showed that GIPR/GLP-1R co-agonists produced greater decreases in body weight and food intake, as well as improved glycemic and lipid outcomes, compared to equal doses of GLP-1 agonists alone.
Finan's current affiliation with Novo Nordisk's Indianapolis Research Center underscores the industry-wide recognition of his expertise. Even as a competitor, his foundational work in explaining the physiological synergy of incretin co-agonism remains a cornerstone of tirzepatide's scientific narrative. He provided the physiological rationale for why two hormones are better than one, demonstrating that GIPR activation could enhance insulin secretion and improve metabolic control in ways that GLP-1 alone could not fully replicate.
4. Kyle W. Sloop: The Architect of Early Viability
While Coskun is often credited with championing tirzepatide's development, Dr. Kyle W. Sloop was the senior research scientist at Eli Lilly who provided the early scientific credibility and mechanistic detail that convinced the organization to invest in the molecule. Sloop was a key co-author on the foundational 2018 paper introducing LY3298176 to the scientific community.
Sloop's work in diabetes research helped establish the early viability of dual receptor targeting. He worked alongside incretin experts to demonstrate that the novel peptide had a signaling profile that was distinct from other options in the pipeline.
Later research, including a landmark 2020 paper published in JCI Insight, revealed a pharmacological property of tirzepatide that Sloop helped characterize: it acts as an "imbalanced and biased" dual agonist. This was a crucial finding. The paper established methodology for calculating receptor occupancy, revealing that at clinically efficacious doses, tirzepatide engages the GIP receptor to a greater degree than the GLP-1 receptor. This "imbalance" is not a flaw; it is a feature. At the GLP-1 receptor, the drug shows "bias," favoring cAMP generation over beta-arrestin recruitment. This biased agonism, where the drug preferentially activates certain signaling pathways (cAMP) while avoiding others (β-arrestin recruitment), may enhance insulin secretion and limit receptor desensitization. Experiments in primary islets revealed that β-arrestin1 limits the insulin response to GLP-1, but not to GIP or tirzepatide. By "imbalancing" the drug toward GIP and avoiding the desensitizing effects of GLP-1, Sloop and his colleagues helped demonstrate why the molecule's pharmacological profile was uniquely tailored for superior metabolic control.
5. Krister B. Bokvist: The Patent Chemist
Behind every great molecule is a robust intellectual property strategy, and at the heart of that strategy for tirzepatide is Krister B. Bokvist. A lead chemist and scientist at Eli Lilly, Bokvist is listed as a primary inventor on the core patents detailing the chemical synthesis, discovery, and structural composition of tirzepatide.
The patents, such as US 9,474,780, cover the specific sequences and chemical modifications that make tirzepatide unique—the fatty acid side chains, the amino acid substitutions, and the methods of production. Bokvist's role as the inventor on these patents places him at the nexus of the drug's commercial success. The legal battles that Eli Lilly has waged to protect these patents, including inter partes review proceedings against generic manufacturers like Empower Pharmacy and BPI Labs, revolve around the claims that Bokvist helped draft.
While less publicly visible than clinical leaders, Bokvist's contribution is foundational. Without the precise chemical engineering detailed in his patents, tirzepatide would not exist in its current, highly effective form. It is the meticulous chemistry of peptide synthesis and optimization that translated the biological concepts of Coskun and DiMarchi into a tangible, manufacturable, and patentable asset.
6. Daniel A. Briere: The Preclinical Pioneer
Dr. Daniel A. Briere, a Senior Director at Eli Lilly, is one of the key figures who ensured that tirzepatide survived the transition from a concept to a clinically viable candidate. He contributed heavily to the preclinical characterization and development of tirzepatide, co-authoring the earliest clinical and safety studies that paved the way for advanced trials.
Briere's work was crucial in establishing the drug's safety profile and understanding its effects on weight loss and metabolism in preclinical models. His research has explored the "weight-independent insulin sensitization" effects of tirzepatide, demonstrating that GIPR agonism mediates improvements in insulin sensitivity beyond what would be expected from weight loss alone. This insight is critical for understanding why tirzepatide is so effective in type 2 diabetes—it not only helps patients lose weight but also directly improves how their bodies process glucose.
Briere has also been involved in the ongoing evolution of the molecule's combination potential. Recent studies presented at major conferences have examined the effects of combining tirzepatide with the selective amylin analog eloralintide. In diet-induced obese rats, the combination produced augmented weight loss greater than the effects of individual therapies. Briere's role in these investigations signals that the tirzepatide story is far from over; it is a platform for future combination therapies.
7. Francis S. Willard: The Signaling Expert
If the 2018 paper announced the arrival of tirzepatide, the 2020 paper authored by Dr. Francis S. Willard explained its genius. Willard, a Lilly scientist, led the critical pharmacological research that detailed tirzepatide's unique signaling pathways.
Willard's highly cited 2020 paper in JCI Insight, "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist," was a tour de force in receptor pharmacology. In it, he and his colleagues established that tirzepatide is not a simple, balanced agonist. It favors the GIP receptor over the GLP-1 receptor and, at the GLP-1 receptor, it acts as a "biased" agonist. This bias—favoring cAMP generation over β-arrestin recruitment—has profound implications.
Beta-arrestins are proteins that often lead to receptor internalization and desensitization. By minimizing β-arrestin recruitment to the GLP-1 receptor, tirzepatide may allow for more sustained signaling and improved efficacy compared to native GLP-1 or some other agonists. This concept of "biased agonism" is one of the most exciting frontiers in modern drug development, and Willard provided the definitive evidence that tirzepatide operates through this mechanism. His work helped explain why a drug that is chemically related to GLP-1 can produce effects that other GLP-1 agonists cannot. It is not just about binding to the receptor; it is about how the binding shapes the receptor's signaling fate.
8. Corina Loghin: The Translational Pharmacologist
A drug that looks great in the laboratory can still fail in the clinic if its pharmacokinetics are wrong. Dr. Corina Loghin, a key clinical pharmacologist at Eli Lilly, played an instrumental role in ensuring that tirzepatide's pharmacokinetic profile was suitable for human use.
Loghin was a co-author of the earliest clinical studies on LY3298176, translating the compound from a laboratory concept into a safe, viable therapeutic for human testing. Her work in clinical pharmacology was essential for determining the correct dosing regimen—specifically, the once-weekly injection schedule that has made the drug so convenient for patients.
One of Loghin's significant contributions was a study published in Diabetes, titled "Renal Impairment Has No Impact on the Clinical Pharmacokinetics of Tirzepatide." This was a critical finding. Patients with diabetes often suffer from renal impairment, and a drug that requires dose adjustment based on kidney function can be difficult to manage. Loghin's study demonstrated that subjects with severe renal impairment had similar pharmacokinetic parameters to healthy subjects, meaning that patients with renal impairment treated with tirzepatide likely do not require dose adjustments. This greatly simplifies the clinical use of the drug and broadens the patient population that can benefit from it.
Loghin's role as the bridge between the lab and the clinic is often the unsung hero of drug development. She ensured that the innovative peptide designed by Coskun and DiMarchi could be delivered effectively to patients without causing unexpected toxicity or requiring prohibitively complex dosing schedules.
9. David D'Alessio: The Clinical Lead
To prove that a drug works, you need rigorous clinical trials, and to lead those trials, you need a clinical academic who commands the respect of the medical community. Dr. David D'Alessio, a prominent endocrinologist at Duke University, served as a crucial clinical lead on the landmark SURPASS clinical trial program, which evaluated tirzepatide's efficacy in managing type 2 diabetes.
D'Alessio's research focuses on the regulation of insulin secretion and glucose tolerance, with a specific focus on the influence of proglucagon-derived peptides on these processes. His academic credibility gave the SURPASS trials added weight. He co-authored several of the key publications that demonstrated tirzepatide's superiority over existing GLP-1 agonists in glycemic control and weight loss. His involvement in the trials evaluating cardiovascular outcomes was particularly significant, as the cardiovascular safety of diabetes drugs is a paramount regulatory concern.
D'Alessio's perspective extends beyond just the data. His research explores the physiologic basis of the incretin effect and the interactions between GLP-1 and GIP. By understanding the fundamental biology, he helped design clinical trials that not only proved tirzepatide works but also illuminated how it works in different patient populations.
10. Ania M. Jastreboff: The Weight Loss Champion
While the SURPASS trials proved tirzepatide's superiority in diabetes, it was the SURMOUNT-1 trial that made it a cultural phenomenon. Dr. Ania M. Jastreboff, Director of the Yale Obesity Research Center, was the lead principal investigator of the pivotal SURMOUNT-1 trial.
Published in the New England Journal of Medicine in 2022, Jastreboff's landmark publication established tirzepatide's unprecedented weight-loss efficacy in adults with obesity. The trial showed that participants with obesity, without diabetes, lost an average of 15-20% of their body weight on the highest doses—a figure previously only achievable through bariatric surgery. This data directly led to the FDA approval of tirzepatide as Zepbound for the treatment of obesity.
Jastreboff's role was critical in shifting the perception of the drug from a "diabetes drug" to a "weight loss drug." She translated the pharmacokinetic and pharmacological profiles into a compelling clinical narrative. In a field historically plagued by ineffective and unsafe medications, Jastreboff provided the evidence that a new era of obesity pharmacotherapy had arrived. She has continued to advocate for the treatment of obesity as a chronic disease, moving away from the stigmatizing view that it is a moral failing requiring only lifestyle modification. Her leadership in SURMOUNT-1 gave millions of patients hope and a clinically proven, effective tool to manage their weight.
The ten scientists profiled here represent a unique confluence of talent. The story of tirzepatide is a masterclass in modern drug development, illustrating how the convergence of peptide engineering (DiMarchi, Bokvist), biological understanding (Coskun, Finan, Sloop), pharmacological precision (Willard, Loghin), and clinical expertise (Briere, D'Alessio, Jastreboff) can produce a transformational therapy.
The impact of their work is already being felt across the healthcare landscape. The success of tirzepatide has sparked a "me-too" and "next-gen" race, with companies pursuing triple agonists (GLP-1/GIP/glucagon) and entirely new mechanisms like the GIP-glucagon approach championed by DiMarchi. The molecule has also opened the door for combination strategies, as evidenced by research pairing tirzepatide with amylin analogs to push weight loss even further.
Yet, the work is not done. The scientists who built tirzepatide are now looking toward its next iterations. Coskun continues to explore combination therapies. DiMarchi is questioning whether GLP-1 is even necessary in the future of weight loss. Finan and D'Alessio are dissecting the basic biology of the incretin system. Jastreboff is leading the charge to ensure that these highly effective drugs are made accessible to the patients who need them.
They proved that the engineering of hormones, guided by a deep understanding of molecular signaling, can achieve what was once thought impossible: a safe, tolerable, and highly effective medical treatment for both diabetes and obesity. In doing so, they have changed the lives of millions—and their legacy will be felt for generations to come.
Sources & further reading
Coskun, T. et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism.
Willard, F.S. et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight.
Jastreboff, A.M. et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine.
DiMarchi, R. et al. — foundational peptide engineering and unimolecular co‑agonist concepts. Indiana University / Eli Lilly.
Finan, B. et al. — preclinical incretin co‑agonist physiology. Novo Nordisk / academic collaborations.
Bokvist, K.B. — core tirzepatide patents (US 9,474,780 et al.).
Briere, D.A., Sloop, K.W., Loghin, C., D’Alessio, D. — preclinical, clinical pharmacology, and SURPASS / SURMOUNT trial contributions.
Comments
Post a Comment